On June 11, 2024, WuXi Biologics resubmitted its disclosure report, revealing changes in its issued and treasury shares. According to the report, as of May 31, 2024, the company's issued shares were 4,262,481,929, and as of the end of June 11, 2024, the balance was 4,153,106,949. During this period, the company issued 154,320, 100,000, 18,000, and 220,700 new shares on June 3, 4, 7, and 11, respectively, under the 2016 share plan. In addition, the company repurchased and cancelled 109,868,000 shares on various dates and as of June 11, 2024, accounting for 2.57756% of the issued shares. On the same day, the company also repurchased 1,810,000 shares which are intended to be cancelled but have not been cancelled yet. All share changes have been formally authorized and approved by the board of directors and are in compliance with all applicable listing rules and laws.

On June 11, 2024, WuXi Biologics resubmitted its disclosure report, revealing changes in its issued and treasury shares. According to the report, as of May 31, 2024, the company's issued shares were 4,262,481,929, and as of the end of June 11, 2024, the balance was 4,153,106,949. During this period, the company issued 154,320, 100,000, 18,000, and 220,700 new shares on June 3, 4, 7, and 11, respectively, under the 2016 share plan. In addition, the company repurchased and cancelled 109,868,000 shares on various dates and as of June 11, 2024, accounting for 2.57756% of the issued shares. On the same day, the company also repurchased 1,810,000 shares which are intended to be cancelled but have not been cancelled yet. All share changes have been formally authorized and approved by the board of directors and are in compliance with all applicable listing rules and laws.